Senior Managing Consultant Radiation Oncology | Clinician Scientist @Uniklinik_Fr. Passionate about #GU cancers + imaging. Views are my own. @ESTRO_RT @degro_ev
Freiburg im Breisgau
Joined October 2010
- Tweets155
- Following560
- Followers506
- Likes741
Simon Spohn retweeted
Excited to be at #ESTRO2026 in Stockholm 🇸🇪 — 11 team members, 14 contributions from the Department of Radiation Oncology University Medical Center Freiburg.
Let’s go! 🎉
#RadiationOncology
@ESTRO_RT
Simon Spohn retweeted
Check out our comment on the WOLVERINE meta analysis just published in @TheLancetOncol !
MDT in prostate cancer is here to stay!
@Simon_Spohn @AncaGrosu1
thelancet.com/journals/lanon…
Simon Spohn retweeted
1st POSITIVE RCT in the #ASTRO2025 Plenary today! #BART meets primary EP of LRFS in High risk MIBC!!!
Simon Spohn retweeted
This is big news 👇 No benefit to prophylactic nodal irradiation in NRG/RTOG 0924
#astro25
@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Simon Spohn retweeted
📣 Last call for #EMUC25 abstracts! 👉Are you ready to showcase your #UrologicalCancer research to help enhance the quality of uro-oncological care?
📅Submit by 1 August, 2025
See topic list & submission details here 👇
emuc.org/scientific-programm…
@myESMO @ESTRO_RT
Simon Spohn retweeted
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
sciencedirect.com/science/ar…
This systematic review and meta-analysis by the DADSPORT Collaboration evaluated the impact of hormone therapy (HT) added to postoperative radiotherapy (RT) in nonmetastatic #ProstateCancer across five randomized controlled trials involving 4,411 participants. While HT did not significantly improve overall survival (OS) in the general population, it did show meaningful benefits in metastasis-free survival (MFS) and prostate cancer–specific survival (PCSS), each with a 4% absolute improvement at 8 years.
Notably, OS benefits may be limited to patients with higher pre-RT PSA levels or CAPRA-S scores.
These findings support the use of adjuvant HT to improve cancer outcomes, particularly in higher-risk patients.
@DrSpratticus
@AmarUKishan
@drjefstathiou
@PCaParker
@_APollack
@PaulSargos
@felixfengmd
@OncoAlert
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima
Simon Spohn retweeted
Great to see many enthusiastic colleagues at our Co-IMPACT meeting. Thanks to all for coming and bringing this huge project forward! #ESTRO2025
Simon Spohn retweeted
@ESTRO_RT Voting is open!!! Would be happy to get your support. See you all in Vienna.
✨ ESTRO Board Elections 2025: Meet Piet Ost, candidate for the Clinical seat at ESTRO. 🗳
👉 Get to know his vision and goals in this short interview: bit.ly/4c16yIf
#ESTROElections
Simon Spohn retweeted
Hot of the press @IJROBP: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial
Full text here: doi.org/10.1016/j.ijrobp.202…
Simon Spohn retweeted
Excited to run for a position in the ESTRO board. Be sure to vote. @ZilliThomas @PaulSargos @VedangMurthy @alison_tree @achoud72 @stephane_supiot @Mat_Guc and all others
ESTRO 2025 Board Elections: Meet the Candidates!
The Board elections are approaching: Two candidates are running for the Physics seats & two for the Clinical seats.
🗳️ Election period: 20 March–20 April
👥 Who can vote? Full ESTRO members (2024 & 2025)
👉shorturl.at/bXRrc
Simon Spohn retweeted
Read our latest #research on #CNNs in radiation oncology, published with @SpringerNature in
Scientific Reports: rdcu.be/dYtp7
@AncaGrosu1 @CZamboglou @Simon_Spohn
Simon Spohn retweeted
Delighted to share the results of #PACE B trial, published in @NEJM today
5 fraction SBRT is non inferior to CRT!
nejm.org/media/doi/full/10.1…
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa
Simon Spohn retweeted
STORM trial results on the treatment of pelvic nodal oligo-recurrence after #ProstateCancer, presented at #ESTRO24: ENRT improves biochemical and locoregional relapse-free survival rates compared with #SBRT.
👉 bit.ly/3Sg1PKd
#Radonc #radiotherapy @alison_tree @piet_ost
Simon Spohn retweeted
👉 Don’t forget to register for the Radiation Therapy in Prostate Cancer Symposium hosted by the Department of Radiation Oncology at @Uniklinik_Fr on the 19th-20th of July 2024
Program and registration via uniklinik-freiburg.de/prosta…
Accredited by @degro_ev
Simon Spohn retweeted
Join us for the Radiation Therapy in Prostate Cancer Symposium in Freiburg on the 19th-20th of July 2024, meet international experts in uro-oncology and present your own research in the poster session.
Programm and registration via uniklinik-freiburg.de/prosta…
Accredited by @degro_ev
Simon Spohn retweeted
@AncaGrosu1 gave a talk on the opportunities of GenAI in #cancer at the #WEF24 in #Davos. AI is a driving force to innovate the fight against cancer 🚀🌍
@degro_ev @ESTRO_RT @Uniklinik_Fr
Simon Spohn retweeted
Relive the highlights and cutting-edge insights from #EMUC23 focusing on:
✅ Multidisciplinary medical care & research
✅ Key sessions on prostate, urothelial & kidney cancers
✅ Game-changing updates on therapies & groundbreaking trials
👉Read the report: bit.ly/3TpVYU6
Simon Spohn retweeted
Circulating tumor DNA to guide #radonc
❓ Beyond status of “promising biomarker” - ready for prime time
Virtual Grand Rounds in Radiation Oncology
Dr. Andreas Rimner
Dec 6th 17:00 – 17:30 CET
Zoom Link 👇
usz.ch/veranstaltung/virtual…
Endorsed by @degro_ev @ESTRO_RT SASRO
Simon Spohn retweeted
People ask about our work to why adjuvant ADT more important than neoadjuvant (or even concurrent)...here you go!
Long overdue and big thanks to Steve Allen and Chao Zhang who worked in my lab @UMichRadOnc to get this paper out. Not easy to get a lab paper out when you leave an institution!
trebuchet.public.springernat…
@SouMyajiT_RO @rtdess @cwspeers @ArulChinnaiyan @drmehrarohit @alison_tree @HimanshuNagarMD @AmarUKishan @DrHowardSandler @jmmrad
Simon Spohn retweeted
Offering post RP salvage RT to patients with BR & -ve PSMA PET remains an open question.
Our multicenter retrospective study demonstrates favorable bRFS after SRT in PSMA PET -ve patients.
@Simon_Spohn @nina_hegemann @CZamboglou @Mat_Guc
link.springer.com/article/10…
